Skip to main content
. 2017 Nov 23;7(12):631. doi: 10.1038/s41408-017-0002-2

Fig. 1. Cumulative incidences of HBV reactivation a, and with or without auto-SCT b.

Fig. 1

HBV reactivation occurred in 7.6% (58/760) of all patients with resolved HBV infection. The cumulative incidences of HBV reactivation at 2 years and 5 years were 7.9% and 14.1%, respectively a. HBV reactivation occurred in 21.1% (38/180) of patients who received auto-SCT treatment and 3.4% (20/580) of patients who received novel agent treatment. The cumulative incidences at 2 years and 5 years in the auto-SCT group were 16% and 30.6%, respectively. The cumulative incidences at 2 and 5 years in the novel agents group were 4.4% and 4.8%, respectively. The incidence rate was significantly higher in the auto-SCT group than in the novel agents group (p < 0.0001) b